{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:35Z","timestamp":1790198495817,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Finnish Cancer Societies"},{"name":"Sigrid Juselius Foundation"},{"name":"Finnish Cancer Institute"},{"DOI":"10.13039\/501100004325","name":"Signe and Ane Gyllenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004325","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013165","name":"Otto A. Malm Foundation","doi-asserted-by":"crossref","award":["4000"],"award-info":[{"award-number":["4000"]}],"id":[{"id":"10.13039\/501100013165","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00432-015-2101-4","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T04:51:28Z","timestamp":1452228688000},"page":"1041-1050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia"],"prefix":"10.1007","volume":"142","author":[{"given":"Mohamed","family":"El Missiry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Adnan Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna L","family":"Rajala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Ekblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Markev\u00e4n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingbritt","family":"\u00c5strand-Grundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Wold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen Rabben","family":"Svedahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Ravn","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Haulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"2101_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"2101_CR2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VHJ et al (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program. Leukemia 17:2474\u20132486. doi: 10.1038\/sj.leu.2403136","journal-title":"Leukemia"},{"key":"2101_CR3","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B et al (2008) Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 12:2107\u20132118. doi: 10.1111\/j.1582-4934.2008.00234.x","journal-title":"J Cell Mol Med"},{"key":"2101_CR4","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","volume":"18","author":"K Cwynarski","year":"2004","unstructured":"Cwynarski K, Laylor R, Macchiarulo E et al (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18:1332\u20131339. doi: 10.1038\/sj.leu.2403401","journal-title":"Leukemia"},{"key":"2101_CR5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","volume":"104","author":"AB Dietz","year":"2004","unstructured":"Dietz AB, Souan L, Knutson GJ et al (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094\u20131099. doi: 10.1182\/blood-2003-12-4266","journal-title":"Blood"},{"key":"2101_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417. doi: 10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"2101_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-9-22","volume":"9","author":"F Fei","year":"2010","unstructured":"Fei F, Yu Y, Schmitt A et al (2010) Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer 9:22. doi: 10.1186\/1476-4598-9-22","journal-title":"Mol Cancer"},{"key":"2101_CR8","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102. doi: 10.1038\/leu.2012.85","journal-title":"Leukemia"},{"key":"2101_CR9","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M et al (2014) Velocity of early BCR\u2013ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28:1988\u20131992. doi: 10.1038\/leu.2014.153","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"2101_CR10","first-page":"S49","volume":"17","author":"J Hasford","year":"1996","unstructured":"Hasford J, Ansari H, Pfirrmann M, Hehlmann R (1996) Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant 17(Suppl 3):S49\u2013S54","journal-title":"Bone Marrow Transplant"},{"key":"2101_CR11","author":"H Hjorth-Hansen","year":"2014","unstructured":"Hjorth-Hansen H, Stenke L, S\u00f6derlund S et al (2014) Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. doi: 10.1111\/ejh.12423","journal-title":"Eur J Haematol"},{"key":"2101_CR12","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270. doi: 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"2101_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H et al (2009) Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135\u2013139. doi: 10.3324\/haematol.13151","journal-title":"Haematologica"},{"key":"2101_CR14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772\u2013782. doi: 10.1182\/blood-2009-12-256800","journal-title":"Blood"},{"key":"2101_CR15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C et al (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587\u20131597. doi: 10.1038\/leu.2011.135","journal-title":"Leukemia"},{"key":"2101_CR16","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/sj.leu.2404807","volume":"21","author":"S Mustjoki","year":"2007","unstructured":"Mustjoki S, Lund\u00e1n T, Knuutila S, Porkka K (2007) Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia 21:2363\u20132368. doi: 10.1038\/sj.leu.2404807","journal-title":"Leukemia"},{"key":"2101_CR17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP et al (2009) Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:1398\u20131405. doi: 10.1038\/leu.2009.46","journal-title":"Leukemia"},{"key":"2101_CR18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A et al (2013a) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914\u2013924. doi: 10.1038\/leu.2012.348","journal-title":"Leukemia"},{"key":"2101_CR19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Richter J, Barbany G et al (2013b) Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 27:1520\u20131526. doi: 10.1038\/leu.2013.19","journal-title":"Leukemia"},{"key":"2101_CR20","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C et al (2013) Combining BCR\u2013ABL1 transcript levels at 3 and 6\u00a0months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121:2739\u20132742. doi: 10.1182\/blood-2012-11-466037","journal-title":"Blood"},{"key":"2101_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","volume":"157","author":"K Ohyashiki","year":"2012","unstructured":"Ohyashiki K, Katagiri S, Tauchi T et al (2012) Increased natural killer cells and decreased CD3+ CD8+ CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 157:254\u2013256. doi: 10.1111\/j.1365-2141.2011.08939.x","journal-title":"Br J Haematol"},{"key":"2101_CR22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/10428194.2010.550074","volume":"52","author":"JJ Powers","year":"2011","unstructured":"Powers JJ, Dubovsky JA, Epling-Burnette PK et al (2011) A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 52:668\u2013679. doi: 10.3109\/10428194.2010.550074","journal-title":"Leuk Lymphoma"},{"key":"2101_CR23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/cbt.27310","volume":"15","author":"Z-Y Qiu","year":"2014","unstructured":"Qiu Z-Y, Xu W, Li J-Y (2014) Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther 15:247\u2013255. doi: 10.4161\/cbt.27310","journal-title":"Cancer Biol Ther"},{"key":"2101_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-012-1116-8","volume":"96","author":"P Rohon","year":"2012","unstructured":"Rohon P (2012) Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 96:1\u20139. doi: 10.1007\/s12185-012-1116-8","journal-title":"Int J Hematol"},{"key":"2101_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 85:387\u2013398. doi: 10.1111\/j.1600-0609.2010.01501.x","journal-title":"Eur J Haematol"},{"key":"2101_CR26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. doi: 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"2101_CR27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR\u2013ABL inhibitors as first-line therapy. Leukemia 26:214\u2013224. doi: 10.1038\/leu.2011.217","journal-title":"Leukemia"},{"key":"2101_CR28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63:789\u2013799","journal-title":"Blood"},{"key":"2101_CR29","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L et al (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 14:2484\u20132491. doi: 10.1158\/1078-0432.CCR-07-4393","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-2101-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2101-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T18:43:10Z","timestamp":1600022590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-2101-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-2101-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]}}}